Meta, Essilorluxottica Sued Over Smartglasses Technology

Investing.com – Russia stocks were higher after the close on Friday, as gains in the Mining, Power and Oil & Gas sectors led shares higher.

At the close in Moscow, the MOEX Russia Index rose 0.32% to hit a new 3-months high.

The best performers of the session on the MOEX Russia Index were MMC NORILSK NICKEL PJSC (MCX:GMKN), which rose 2.15% or 3.50 points to trade at 165.40 at the close. Meanwhile, Rostelekom PJSC (MCX:RTKM) added 1.71% or 1.09 points to end at 64.70 and Gazprom PJSC (MCX:GAZP) was up 1.48% or 1.86 points to 127.60 in late trade.

The worst performers of the session were ROSSETI PJSC (MCX:FEES), which unchanged 1.38% or 0.00 points to trade at 0.07 at the close. Federal Hydro Generating Company RusHydro PJSC (MCX:HYDR) declined 1.24% or 0.01 points to end at 0.42 and AK ALROSA PJSC (MCX:ALRS) was down 0.59% or 0.25 points to 41.91.

Rising stocks outnumbered declining ones on the Moscow Stock Exchange by 153 to 87 and 13 ended unchanged.

Shares in MMC NORILSK NICKEL PJSC (MCX:GMKN) rose to 52-week highs; up 2.15% or 3.50 to 165.40.

The Russian Volatility Index – RVI, which measures the implied volatility of MOEX Russia Index options, was up 0.83% to 25.36.

Gold Futures for February delivery was up 1.35% or 66.49 to $4,979.89 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in March rose 3.22% or 1.91 to hit $61.27 a barrel, while the March Brent oil contract rose 3.29% or 2.11 to trade at $66.17 a barrel.

USD/RUB was down 0.65% to 75.50, while EUR/RUB fell 0.02% to 89.31.

The US Dollar Index Futures was down 0.91% at 97.29.

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock surged 11% Friday after the company announced plans to present 3-year topline functional results from its Phase 3 EMBARK study of ELEVIDYS in Duchenne muscular dystrophy patients.

The biotech firm, which specializes in precision genetic medicine for rare diseases, will host a webcast and conference call on Monday, January 26, 2026, at 8:30 am Eastern Time to discuss the data from Part 1 of the global, randomized placebo-controlled study. The trial evaluated ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at the time of treatment.

Investors appear to be reacting positively to the upcoming presentation of longer-term data for ELEVIDYS, which received accelerated approval from the FDA in 2023 for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.

The webcast will be available under the investor relations section of Sarepta’s website, with a replay archived for one year following the event. Participants joining by phone will need to register through an online form to receive dial-in details.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

MiniMed Group (MMED) has for a proposed Nasdaq IPO.

The company describes itself as: "We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes.
Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system. This allows us to provide a five-star customer experience: an easier and consistent user experience, seamless integration, privacy and security, optimized performance and reliability, and our pioneering and industry-leading dosing algorithm, based on time in range (“TIR”) outcomes in real-world data. This differentiated value proposition is designed to solve two key problems for people with diabetes (“PWD”). First, we believe our products deliver superior health outcomes, when measured against European Association for the Study of Diabetes (“EASD”) and American Diabetes Association (the “ADA”) guidelines, by effectively and measurably improving glycemic control compared to other available treatment options and competing products. By enhancing glycemic control, our products can help reduce long-term complications of diabetes, improve longevity and quality of life, and reduce associated costs to health systems. Second, our customer experience reduces or substantially eliminates the burden of diabetes management for users, their families, their caregivers, and their healthcare providers (“HCPs”)."

Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley will serve as lead underwriters.

Investing.com -- Digital Currency X Technology Inc. (NASDAQ:DCX) stock tumbled 13.7% in after-hours trading Friday after the company disclosed it received a delisting notification from Nasdaq due to failure to maintain the minimum bid price requirement.

The digital asset treasury management firm announced it had received a written notice on January 20, 2026, stating it was not in compliance with Nasdaq’s rule requiring a minimum closing bid price of $1.00 per share. DCX’s shares traded below this threshold for 30 consecutive business days from December 4, 2025, through January 16, 2026.

Unlike standard cases where companies receive a 180-day compliance period, DCX is ineligible for this grace period due to having implemented one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.

According to the notice, DCX’s securities will be delisted from the Nasdaq Capital Market and suspended at market open on January 29, 2026, unless the company successfully appeals the determination by January 27.

The company stated it plans to request a hearing before the Nasdaq Hearings Panel to appeal the notice. DCX recently implemented a 12-for-1 share consolidation with a market effective date of January 22, 2026, in an attempt to regain compliance with the minimum bid price requirement.

However, the company acknowledged there are no assurances it will be able to regain or maintain compliance with Nasdaq listing standards, or that its appeal will be successful.

Digital Currency X Technology describes itself as a digital asset treasury management company focused on cryptocurrency custody and storage solutions, with treasury holdings reportedly exceeding $1.4 billion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- The S&P 500 eked out a gain Friday, but stilled slumped to second-consecutive weekly loss Friday, as a slump Intel on disappointing earnings and week of geopolitical tensions weighed. 

At 4:00 p.m. ET (18:15 GMT), the Dow Jones Industrial Average dropped 285 points, or 0.6%, the S&P 500 index gained 0.02%, and the NASDAQ Composite 0.3%.

The main averages on Wall Street gained on Wednesday and Thursday, rebounding after sharp losses at the start of the week, but they are still on course for their second negative week in a row.

Get more analysis and top US stock picks by upgrading to InvestingPro

Greenland deal brings relief

Sentiment received a boost in the second half of the week after U.S. President Donald Trump said his administration had reached a framework trade deal over Greenland, and that he will not tariff European powers in an attempt to coerce control over the Danish territory. 

Trump also withdrew his threat to use force to take the island, a sharp reversal from his rhetoric last week. The move offered much relief to markets, after Trump’s earlier tariff threats ramped up global geopolitical tensions and sparked deep losses in Wall Street.

That said, the relationship between many European countries and the Trump administration remains fraught, and the U.S. president added to geopolitical tensions by flagged potential military action against Iran, stating the U.S. had a fleet moving towards the Middle East country as he spoke to reporters aboard Air Force One late Thursday, warning Tehran against killing protesters or restarting its nuclear efforts.

“We have an armada... heading in that direction, and maybe we won’t have to use it,” Trump told reporters. “I’d rather not see anything happen, but we’re watching them very closely,” Trump said. 

Intel slumps on disappointing outlook 

Turning to the corporate sector, Intel (NASDAQ:INTC) stock slumped after the chipmaker reported a fourth-quarter loss and unveiled a dour outlook for the current quarter.

The company, who has recently been buoyed by fresh backing from major investors including artificial intelligence-darling Nvidia and even the U.S. government, posted a net loss of $333 million for the final three months of its fiscal year, worse than Wall Street analysts had anticipated.

Executives flagged the impact of soaring demand from data centers, which house the chips that power cutting-edge AI models. CFO David Zinsner described supply shortages as an industry-wide problem that could extend well into 2026.

There are more major earnings from the tech sector to digest next week, with Apple(NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN) and Tesla (NASDAQ:TSLA) all set to report.

Elsewhere, Nvidia (NASDAQ:NVDA) stock rose after Bloomberg reported that Chinese authorities have told major technology companies they can prepare orders for the tech giant’s H200 AI chips, suggesting Beijing may be close to formally approving imports of these critical AI components.

Intuitive Surgical (NASDAQ:ISRG) stock rose after the medical device maker beat Wall Street ‍estimates for fourth-quarter profit and revenue on growing demand for its ⁠surgical robots used in minimally invasive procedures.

Booz Allen Hamilton (NYSE:BAH) stock rose after the advanced technology company reported third-quarter fiscal 2026 results that beat expectations despite revenue declines, with investors focusing on the company’s strong profitability metrics.

Fed to meet next week 

The economic data slate includes S&P PMI data for January later Friday, as well as the Michigan consumer sentiment index, but these releases are unlikely to change sentiment ahead of next week’s Federal Reserve meeting.

The central bank is widely expected to leave interest rates unchanged, amid growing uncertainty over the U.S. economy. 

Trump confirmed Thursday that he has concluded his search for the next Federal Reserve chair after interviewing a final shortlist of candidates.

The current shortlist of potential nominees features a mix of institutional insiders and private sector veterans. Included in the final deliberations are National Economic Council Director Kevin Hassett, BlackRock executive Rick Rieder, current Fed Governor Christopher Waller, and former governor Kevin Warsh. 

Peter Nurse, Amber Warrick contributed to this article